Participating VQI centers range from outpatient sites to large health systems ensuring a wide range of data for improving quality of care and patient safety CHICAGO–(BUSINESS WIRE)–The Society for Vascular Surgery® Vascular Quality Initiative® (SVS VQI) clinical registry announced today it has achieved another milestone with more than 1,000 centers enlisted in […]
Coronary/Structural Heart
“Vesteck, Inc. Successfully Completes Five Clinical Cases”
WEST CHESTER, Pa., April 6, 2023 /PRNewswire/ — VESTECK, Inc. is pleased to announce the successful completion of 2 additional clinical cases with the “SUTURE-TIGHT” TM device. VESTECK, Inc., Scientific Advisory Board member Dr. Venkatesh Ramaiah along with Dr. Bao Bui, performed 2 EVAR procedures with the “SUTURE-TIGHT”TM catheter, helping patients number 4 and 5 in Sherbrook, Canada. […]
Icentia Receives U.S. Food and Drug Administration (FDA) Clearance for CardioSTAT®
QUEBEC CITY, April 6, 2023 /PRNewswire/ — Icentia Inc., today announced that it has received FDA 510(k) clearance for CardioSTAT, an ambulatory, continuous ECG monitoring solution that relies on a wire free, single-use recorder. “This approval marks a key milestone for our company. The FDA clearance opens the door to the world’s largest […]
Endotronix Announces Enrollment Completion of PROACTIVE-HF Pivotal Trial
Data to support regulatory submission and accelerate U.S. market access for the Cordella™ Pulmonary Artery (PA) Sensor Cordella™ is the first and only patient management platform to provide both critical PA pressure data, using an implanted sensor, and noninvasive vitals (blood pressure, heart rate, and weight) for comprehensive clinical management delivered in […]
BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies
SUNNYVALE, Calif., April 04, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the issuance of two patent grants related to enabling technologies for delivery of its investigational autologous and allogeneic cell therapies. The United States […]
Repairon Announces Completion of Dose-Finding Part of BioVAT-HF Phase 1/2 Trial in Advanced Heart Failure
Feasibility and safety demonstrated in patients with advanced heart failure Safe maximal dose for continuation into Phase 2 (Proof-of-Concept) identified Proof for successful heart remuscularization obtained Interim data on 15 patients with 800 million cells dose expected in Q2 2024 GÖTTINGEN, Germany, April 04, 2023 (GLOBE NEWSWIRE) — Repairon, a […]
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel’s Ministry of Health
— Approval of VAZKEPA® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk Characteristics as Studied in REDUCE-IT –- — Heart Disease Second Leading Cause of Death in Men and Women Aged 45 and Older in Israel […]
Morton Plant Hospital’s Patients Reap Benefits from Heart Team’s Vision
CLEARWATER, Fla., April 3, 2023 /PRNewswire/ — Eleven years ago on Feb. 2, 2012, Morton Plant Hospital in Clearwater became the first hospital in the Tampa Bay area to replace a heart valve without open heart surgery. The structural heart team, led by Joshua Rovin, MD, FACS, cardiovascular surgeon and medical director of The Center for Advanced Valve and […]
Semler Scientific Comments on CMS Risk Adjustment Changes in the 2024 Medicare Advantage and Part D Final Rate Announcement
SANTA CLARA, Calif., April 3, 2023 /PRNewswire/ — Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, commented on the recent Centers for Medicare and Medicaid Services (CMS) 2024 Medicare Advantage and Part D Final Rate Announcement. “Semler Scientific remains confident that screening […]
Sequana Medical announces submission of Investigational New Drug (IND) application for DSR® 2.0 for treatment of congestive heart failure
Ghent, Belgium – 03 April 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on 31 March 2023 for its second-generation […]



